The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $343,744 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the University of California, Los Angeles (UCLA) to develop a comprehensive product development strategy and clinical implementation plan for an investigational new drug (IND) application for a hematopoietic stem/progenitor cell-based chimeric antigen receptor (CAR) gene therapy to potentially cure HIV infection. The research aims to systematically develop an optimized HIV-specific CAR approach, establish a regulatory strategy, and work towards initiating Phase I clinical trials to evaluate the safety and feasibility of this novel curative therapy for HIV. The award commenced on December 6, 2024 and is scheduled for completion by November 30, 2025.
Generated 4/1/25, 1:58 AM